Healthcare Providers and Services
Company Overview of Cancer Treatment Centers of America, Inc.
Cancer Treatment Centers of America, Inc. owns and operates cancer care hospitals. It offers medical oncology, surgical oncology, radiation oncology, hematologic oncology, and neurosurgery services; nutrition therapy, pain management, naturopathic medicine, mind-body medicine, oncology rehabilitation, and spiritual support; care management, patient relations, culinary services, outpatient accommodations, transportation, and activities and classes services; acupuncture, chiropractic care, survivorship support, patient education, pharmacy, and HCAHPS comparison services; and interventional pulmonology, gastroenterology, and interventional radiology services. Cancer Treatment Centers of America...
1336 Basswood Road
Schaumburg, IL 60173
Founded in 1988
Key Executives for Cancer Treatment Centers of America, Inc.
Chief Executive Officer and President
Founder and Chairman of the Board
Chief Medical Information Officer, Senior Vice President of Information Services and Naturopathic Physician
Chief Executive Officer of Eastern Regional Medical Center and President of Eastern Regional Medical Center
Compensation as of Fiscal Year 2014.
Cancer Treatment Centers of America, Inc. Key Developments
Cancer Treatment Centers of America Launches Phase IIi of Innovative ‘Pembroplus’ Clinical Trial
Apr 27 15
Cancer Treatment Centers of America has begun the Phase II portion of the first of six arms of this first-of-its-kind clinical trial, using a new immunotherapy treatment for patients with advanced small cell lung cancer, pancreatic cancer and connective-tissue cancers, including breast cancer. This innovative “PembroPlus” clinical trial combines an immunotherapy drug with already FDA-approved chemotherapy drugs (gemcitabine, docetaxel, nab-paclitaxel, vinorelbine, irinotecan, and/or liposomal doxorubicin). The addition of pembrolizumab is aimed at activating the body’s own immune system to improve the results that otherwise might be achieved from chemotherapy alone. This combination of chemotherapy drugs is investigational in this study. A patient with advanced-stage triple negative breast cancer received the first Phase II treatment on April 23. Triple negative breast cancer is one of the most aggressive and difficult to treat of all breast cancers. The term triple negative refers to the fact that this type of cancer tests negative for estrogen receptors, progesterone receptors and the HER2 protein, and therefore does not respond to hormonal therapy or therapies that target HER2 receptors. Studies have shown that triple negative breast cancer is more likely to spread beyond the breast and more likely to recur after initial treatment. The study will enroll up to 140 patients who have exhausted previous standard-of-care treatments and are now eligible for clinical trial studies. It includes patients with advanced small cell lung cancer, pancreatic cancer, breast cancer, and a variety of sarcomas, which are cancers of the body’s connective tissues, including muscles, fat, nerves and bones.
Cancer Treatment Centers of America Launches Clinical Trial Combining Chemotherapy and Immunotherapy
Jan 14 15
Cancer Treatment Centers of America (CTCA) at Western Regional Medical Center (Western) in Goodyear, Arizona is now accepting patients into a clinical trial that combines more traditional chemotherapy drugs (gemcitabine, docetaxel, nab-paclitaxel, vinorelbine, irinotecan, and/or liposomal doxorubicin) with immunotherapy (pembrolizumab), activating the body’s own immune system to improve upon results that may be achieved from chemotherapy alone. Uniquely, the PembroPlus Phase Ib and Phase II study will target patients with advanced metastatic sarcoma, small cell lung cancer, and pancreatic adenocarcinoma. There are anticipated to be up to 140 patients enrolled on this multi-arm study. Recent data reported in the New England Journal of Medicine1 and Lancet2 demonstrates promising results with antibody-based immunostimulatory therapy in treating melanoma, renal cell carcinoma, and non-small cell lung cancer. Data has also shown synergetic effects of utilizing cytotoxic chemotherapy in combination with immunostimulatory therapy. PembroPlus will build upon this data, extending treatment options to additional cancer types.
Cancer Treatment Centers of America Names Nancy Hesse as its Chief Nursing Officer
Nov 10 14
Cancer Treatment Centers of America has named Nancy Hesse, MSN, RN, as its Chief Nursing Officer. Hesse previously held the position of SVP, Patient of Care Services at CTCA - Eastern Regional Medical Center and will continue in that role while assuming her new position. In this position, Hesse will be responsible for leading the development and execution of system-wide programs and best practices for safety outcomes and clinical quality. Utilizing her leadership skills, Hesse will be the voice of nursing for CTCA to ensure that the nursing staff is heard and accounted for in organizational decisions. Hesse joined CTCA in January 2014 after serving as Chief Nursing Officer at Abington Health, Lansdale Hospital.
Similar Private Companies By Industry
Recent Private Companies Transactions